Cencora Inc.
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are down following the company's Q4 earning...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healt...
Latest News
23 hours ago · marketbeat.com
What Cencora (COR) Said on Its Q4 Earnings CallCencora NYSE: COR reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distribution business.
1 day ago · zacks.com
Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins ExpandCOR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
1 day ago · seekingalpha.com
Cencora, Inc. (COR) Q4 2026 Earnings Call TranscriptCencora, Inc. (COR) Q4 2026 Earnings Call Transcript
1 day ago · zacks.com
Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
1 day ago · zacks.com
Cencora (COR) Surpasses Q4 Earnings and Revenue EstimatesCencora (COR) came out with quarterly earnings of $4.66 per share, beating the Zacks Consensus Estimate of $4.56 per share. This compares to earnings of $3.84 per share a year ago.
1 day ago · businesswire.com
Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and FocusCONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two years, Cencora has taken significant steps to advance our strategy through investments to further our leadership in specialty and enhance our service to our customers and partners. Our realigned organizational structure reflects our focus on ensuring Cencora is uniquely positioned as a leader in suppo.
1 day ago · businesswire.com
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End ResultsCONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.71 for the fourth quarter of fiscal 2026, compared to $(1.75) in the prior year quarter. Adjusted diluted EPS, which is a no.
2 days ago · zacks.com
Why Cencora (COR) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
6 days ago · zacks.com
Cencora Gears Up to Report Q4 Results: How to Play the Stock?COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.
6 days ago · zacks.com
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key MetricsLooking beyond Wall Street's top-and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove COR